Genmab(US:GMAB)2026-02-17 20:24Share Buy-Back Program - Genmab is initiating a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of 725 million DKK[3] - The share buy-back program will commence on February 18, 2026, and is expected to conclude no later than March 31, 2026[2] - The share buy-back will be executed on Nasdaq Copenhagen and Multilateral Trading Facilities, adhering to specific price and volume conditions[4] - Genmab has entered into a non-discretionary instruction with Danske Bank for the execution of the buy-back program[3] - The maximum price for shares purchased will not exceed the higher of the latest independent transaction price or the highest independent bid price at the time of the transaction[5] - The total number of shares that may be purchased on a single trading day will not exceed 25% of the average daily trading volume over the preceding 20 trading days[5] - Weekly announcements will be issued regarding transactions made under the buy-back program[6] Treasury Shares - As of February 17, 2026, Genmab holds 2,615,851 treasury shares, representing 4.07% of the share capital[6] Commitment to Stock Programs - Genmab is committed to honoring its obligations under the Restricted Stock Unit program through this buy-back initiative[8] Business Focus - Genmab's focus remains on advancing innovative antibody medicines for cancer and other serious diseases[7]